Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study
Authors' conclusion
This real-world observational study shows that initiation of iGlarLixi in people with T2D inadequately controlled on oral antidiabetic drugs ± basal insulin or GLP-1 RAs improves glycaemic control with a low incidence of hypoglycaemia.
Study context
- Population
- Adults (≥18 years) with T2D inadequately controlled with oral antidiabetic drugs ± basal insulin or GLP-1 RAs who had initiated iGlarLixi within 1 month prior to inclusion; mean age 57.8 (SD 11.2) years, 49% male685 with HbA1c data
- Participants
- 737 adults
- Outcome
- Change in HbA1c from baseline
- Follow-up
- Month 6
Methodological detailsinternational, multicentre, 12-month, real-world, Data collected at inclusion, month 3, month 6 and month 12 from patient diaries, self-measured plasma glucose and questionnaires
- International
- Multicentre
- 12-month
- Real-world
- Data collected at inclusion, month 3, month 6 and month 12 from patient diaries, self-measured plasma glucose and questionnaires
Main finding
As reported in the abstract
Change in HbA1c from baseline (LS mean)
LS mean change in HbA1c from baseline to month 6
−1.4%
SE 0.05; 95% CI −1.5, −1.3
Observational data: associations, not effects.
Further findings
- Absolute change in HbA1c from baseline at month 12
- −1.7% ± 1.9% (95% CI: −1.9, −1.5)
Safety
Hypoglycaemia · study period
- Hypoglycaemia events reported
- 72
- Severe hypoglycaemia (participants)
- 2
- Severe hypoglycaemia rate
- 0.003 events per patient-year
Original publication
Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study. Diabetes Obes Metab. Published 18 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →